Effects of doxycycline on clinical, microbiological and immunological parameters in well‐controlled diabetes type‐2 patients with periodontal disease: a randomized, controlled clinical trial

Abstract

Adjunctive systemic doxycycline does not seem to significantly enhance the effects of SRP in well-controlled diabetes type 2 patients.

Targeting matrix metalloproteinases with intravenous doxycycline in severe sepsis – A randomised placebo-controlled pilot trial

“…The arthritis-and dental studies showed a decrease in MMP-8-levels in saliva and gingival crevicular fluid (GCF). However, in a recent randomised, placebo-controlled study of 66 patients measuring MMP-8 in GCF in doxycycline treated patients vs. placebo-treated no difference in MMP-8 levels was detected [45]. This is in accordance with our results with the exception that we did not measure MMP-8 from the effect site but from plasma.…”

Efficacy of systemic antibiotics in nonsurgical periodontal therapy for diabetic subjects: a systematic review and meta-analysis

“…One study reported that diarrhoea (three subjects in the control group and seven in the test group), headache (one patient in the control group and four in the test group), metallic taste (two patients in the control group and four in the test group) and nausea/vomiting (two participants in the control group and five in the test group) were adverse effects informed by the participants. Another study reported that one female patient in the control group reported dizziness and difficulty in swallowing. Only one trial reported that there were no adverse events.…”

Systematic review and meta-analysis on the nonsurgical treatment of chronic periodontitis by means of scaling and root planing with or without adjuncts

“…The study investigators reported on 6 major groups of antimicrobials: amoxicillin and metronidazole combination therapy, 18,44,45,47,50,55,60 metronidazole, 39,52,61 erythromycin analogues (azithromycin 39,46,49,51,[56][57][58][59] and clarithromycin 53 ), moxifloxacin 48 (a fourth-generation fluoroquinolone antibacterial agent), and others (for example, tetracycline 20,43,54 and doxycycline 22,48,62 as the antimicrobial dose of doxycycline, not to be confused with SDD, which is covered in a separate section). The variety of dosing regimens used for each systemic antimicrobial drug is described elsewhere.…”

“…Compared with SRP alone, SRP plus systemic antimicrobials resulted in a 0.35-mm mean gain in CAL (95% CI, 0.20-0.51) ( Figure 5). 18,20,22,39,[43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62] We judged the overall level of certainty in the evidence to be moderate on the basis of the evidence profile in Table 3.…”